Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Author(s):: Heijde, D. van der; Baraliakos, X.; Gensler, L.S.; Maksymowych, W.P.; Tseluyko, V.; Nadashkevich, O.; Abi-Saab, W.; Tasset, C.; Meuleners, L.; Besuyen, R.; Hendrikx, T.; Mozaffarian, N.; Liu, K.; Greer, J.M.; Deodhar, A.; Landewe, R.

Published: 2018
Publication type: Article / Letter to editor

Date issued: 2018-12-01
Language: English
Is part of: Lancet (2018), Vol. 392, no. 10162, p. 2378-2387
hdl: 1887/77621
doi: 10.1016/S0140-6736(18)32463-2
URL: https://escholarship.org/uc/item/98d1m6ss#main